Candel reported an additional 12 months of follow-up from an ongoing phase 2a trial evaluating aglatimagene besadenovec (CAN-2409) plus valacyclovir with continued immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients with inadequate response to prior immune checkpoint inhibitors. In the per-protocol population (n=46), 50% of patients were alive at 24 months and median overall survival was 25.4 months. In cohort 2 (n=41) with progressive disease at baseline despite prior immune checkpoint inhibitor therapy, median overall survival was 21.5 months. Among patients surviving beyond 24 months with PD-L1 status available (n=20), 85% had baseline PD-L1 tumor proportion scores below 50%. The company said it plans to initiate a phase 3 trial in the second quarter of 2026 in patients with non-squamous histology.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603170805PRIMZONEFULLFEED9673250) on March 17, 2026, and is solely responsible for the information contained therein.
Comments